These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital. Szoeke CE; Parsons MW; Butcher KS; Baird TA; Mitchell PJ; Fox SE; Davis SM Med J Aust; 2003 Apr; 178(7):324-8. PubMed ID: 12670274 [TBL] [Abstract][Full Text] [Related]
10. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341 [TBL] [Abstract][Full Text] [Related]
11. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. Albers GW; Bates VE; Clark WM; Bell R; Verro P; Hamilton SA JAMA; 2000 Mar; 283(9):1145-50. PubMed ID: 10703776 [TBL] [Abstract][Full Text] [Related]
12. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital. Hsu YC; Sung SF; Ong CT; Wu CS; Su YH Acta Neurol Taiwan; 2009 Mar; 18(1):14-20. PubMed ID: 19537569 [TBL] [Abstract][Full Text] [Related]
14. TPA use for stroke in the Registry of the Canadian Stroke Network. Nadeau JO; Shi S; Fang J; Kapral MK; Richards JA; Silver FL; Hill MD; Can J Neurol Sci; 2005 Nov; 32(4):433-9. PubMed ID: 16408572 [TBL] [Abstract][Full Text] [Related]
15. Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience. Lattimore SU; Chalela J; Davis L; DeGraba T; Ezzeddine M; Haymore J; Nyquist P; Baird AE; Hallenbeck J; Warach S; Stroke; 2003 Jun; 34(6):e55-7. PubMed ID: 12750543 [TBL] [Abstract][Full Text] [Related]
16. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. Katzan IL; Furlan AJ; Lloyd LE; Frank JI; Harper DL; Hinchey JA; Hammel JP; Qu A; Sila CA JAMA; 2000 Mar; 283(9):1151-8. PubMed ID: 10703777 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials. Ramakrishnan TCR; Kumaravelu S; Narayan SK; Buddha SS; Murali C; Majeed PHA; Meenakshi-Sundaram S; Wadia RS; Sharma V; Basu I; Vijaya P; Salam KA; Barmare S; Vaid Z; Nirmal Raj KK; Wattamwar PR; Asokan K; Dhonge V; Nellikunja S; Namjoshi D; Srinivasa R; Laddhad DS; Deshpande SD; Raghunath B; Kalita J; Kumar M; Misra UK; Pradeep M; Am J Cardiovasc Drugs; 2018 Oct; 18(5):387-395. PubMed ID: 29948822 [TBL] [Abstract][Full Text] [Related]
18. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Grotta JC; Burgin WS; El-Mitwalli A; Long M; Campbell M; Morgenstern LB; Malkoff M; Alexandrov AV Arch Neurol; 2001 Dec; 58(12):2009-13. PubMed ID: 11735774 [TBL] [Abstract][Full Text] [Related]
19. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients. Berrouschot J; Röther J; Glahn J; Kucinski T; Fiehler J; Thomalla G Stroke; 2005 Nov; 36(11):2421-5. PubMed ID: 16210554 [TBL] [Abstract][Full Text] [Related]
20. Intraarterial thrombolytic therapy within 3 hours of the onset of stroke. Bourekas EC; Slivka AP; Shah R; Sunshine J; Suarez JI Neurosurgery; 2004 Jan; 54(1):39-44; discussion 44-6. PubMed ID: 14683539 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]